Robert W. Ross, Matthew D. Galsky, Phil Febbo, Marc Barry, Jerome P. Richie, Wanling Xie, Fiona M. Fennessy, Rupal S. Bhatt, Julia Hayes, Toni K. Choueiri, Clare M. Tempany, Philip W. Kantoff, Mary E. Taplin and William K. Oh Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer Cancer 118
Version of Record online: 26 JAN 2012 | DOI: 10.1002/cncr.27416
Neoadjuvant docetaxel combined with bevacizumab is safe and results in reductions in both tumor volume and serum prostate-specific antigen in men with high-risk localized prostate cancer. The role of neoadjuvant chemotherapy in prostate cancer, and perioperative antiangiogenic therapy in general, requires further elucidation through ongoing and planned trials.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field